Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer
暂无分享,去创建一个
Shujiro Okuda | A. Protopopov | E. Oki | S. Kudo | F. Ishida | K. Akazawa | T. Wakai | S. Lyle | K. Takabe | H. Ichikawa | T. Konishi | Yusuke Muneoka | Y. Shimada | M. Nagahashi | J. Sakata | T. Ishikawa | Takashi Kobayashi | Yiwei Ling | H. Takaishi | Y. Kitagawa | M. Nakano | S. Maruyama | T. Hayashida | H. Kameyama | Y. Takii | Yosuke Tajima | H. Nogami | R. Yagi | Takuma Okamura | J. Ring | Hitoshi Nogami
[1] Shujiro Okuda,et al. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer. , 2017, Human pathology.
[2] E. Van Cutsem,et al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials , 2017, JAMA oncology.
[3] S. Barni,et al. Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis , 2017, JAMA oncology.
[4] Shujiro Okuda,et al. Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine , 2016, Genome Medicine.
[5] Hiromu Suzuki,et al. Molecular differences in the microsatellite stable phenotype between left‐sided and right‐sided colorectal cancer , 2016, International journal of cancer.
[6] J Ricke,et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] Jeffrey S. Morris,et al. Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer , 2016, British Journal of Cancer.
[8] R. Scharpf,et al. The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer , 2015, Nature.
[9] H. Lenz,et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. , 2015, Journal of the National Cancer Institute.
[10] X. Fang,et al. Different treatment strategies and molecular features between right-sided and left-sided colon cancers. , 2015, World journal of gastroenterology.
[11] D. Bernardo,et al. Is right-sided colon cancer different to left-sided colorectal cancer? - a systematic review. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[12] J. Kench,et al. Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.
[13] J. Tabernero,et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.
[14] J. Edwards,et al. The relationship between tumour site, clinicopathological characteristics and cancer‐specific survival in patients undergoing surgery for colorectal cancer , 2012, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[15] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[16] K. Sugihara,et al. Tumor location is a prognostic factor in poorly differentiated adenocarcinoma, mucinous adenocarcinoma, and signet-ring cell carcinoma of the colon , 2012, International Journal of Colorectal Disease.
[17] Maureen A. Smith,et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Davide Corà,et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.
[19] P. Gibbs,et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer , 2011, Cancer.
[20] D. Kerr,et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] E. Van Cutsem,et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.
[22] M. Lai,et al. Colorectal cancer, one entity or three , 2009, Journal of Zhejiang University SCIENCE B.
[23] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[24] Neal J Meropol,et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] B. Iacopetta. Are there two sides to colorectal cancer? , 2002, International journal of cancer.
[26] A. Børresen-Dale,et al. Different genetic pathways to proximal and distal colorectal cancer influenced by sex‐related factors , 1997, International journal of cancer.
[27] V. Heinemann,et al. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. , 2017, European journal of cancer.
[28] D. Brizel,et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .
[29] F. Bosman,et al. WHO Classification of Tumours of the Digestive System , 2010 .
[30] Christopher Willett,et al. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.